Replies to post #192451 on Biotech Values

[DewDiligence]

MYL takes option on ex-US rights to PULM’s PUR0200, a LAMA for COPD:

http://finance.yahoo.com/news/pulmatrix-mylan-enter-ex-u-113000190.html

Financial terms have not been disclosed.

Separately, PULM announced a new drug candidate, PUL1900, an inhaled anti-fungal drug for patients with CF (http://finance.yahoo.com/news/pulmatrix-announces-first-inhaled-anti-113000215.html ).

PULM is the product of a recent reverse merger (#msg-114559267).

[DewDiligence]

PULM reverse-merges with—(private)—Cullgen Inc:

https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html

…upon the closing of the merger, pre-merger Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen stockholders are expected to own approximately 96.4% of the combined company which will operate under the name Cullgen Inc., be headquartered in San Diego, CA and trade on The Nasdaq Capital Market…

…Cullgen is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. The Company applies its proprietary uSMITE (ubiquitin-mediated, small molecule-induced target elimination) platform to expand the drug design paradigm beyond functional site inhibition, enabling the targeting of historically "undruggable" proteins for selective destruction.

PULM is itself the (failed) product of a 2015 reverse-merger (#msg-114559267).